Cytokine function: A study in biologic diversity

American Journal of Clinical Pathology

Volumn 105, Issue 5, 1996, Pages 589-598

  Cohen, Marion C ^a   Cohen, Stanley ^a  

^a RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

Author keywords

Growth factor; Interferon; Interleukin; Lymphokine; Monokine

Indexed keywords

ALPHA INTERFERON; CHEMOKINE; CYTOKINE; ERYTHROPOIETIN; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HEMOPOIETIC GROWTH FACTOR; INTERFERON; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 2; LYMPHOKINE; MONOKINE; TRANSFORMING GROWTH FACTOR BETA;

ANEMIA; BONE MARROW SUPPRESSION; CELL DESTRUCTION; CELL DIFFERENTIATION; CELL MOTILITY; CELL PROLIFERATION; CLINICAL TRIAL; HOMEOSTASIS; HOST RESISTANCE; HUMAN; IMMUNE RESPONSE; INFLAMMATION; KIDNEY CARCINOMA; MELANOMA; NEUTROPENIA; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; REVIEW; SIGNAL TRANSDUCTION;

EID: 0029937810     PISSN: 00029173     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajcp/105.5.589     Document Type: Review

References (125)

1. Arai K, Lee F, Miyajima A, et al. Cytokines: Coordinators of immune and in inflammatory responses. Ann Rev Biochem 1990;59:783-836.
2. Cohen S, Bigazzi PE, Yoshida T. Commentary: Similarities of T cell function in cell-mediated immunity and antibody production. Cell Immunol 1974;12:150-159.
3. Bloom BR, Bennett B. Mechanism of a reaction in vitro associated with delayed-type hypersensitivity. Science 1966;153:80-82.
4. David JR. Delayed hypersensitivity in vitro: Its mediation by cell-free substances formed by lymphoid cell-antigen interaction. Proc Natl Acad Sci USA 1966;56:72-77.
5. Wheelock EF. Interferon-like virus-inhibitor induced in human leukocytes by phytohemagglutinin. Science 1965;149:310-311.
6. Waksman BH. Overview: Biology of the lymphokines. In: Cohen S, Pick E, Oppenheim JJ, eds. Biology of the Lymphokines. New York: Academic Press, 1979, pp 585-616.
7. Kelso A. The enigma of cytokine redundancy. Immunol Cell Biol 1994;72:97-101.
8. Baron S, Tyring SK, Fleischmann WR, et al. The interferons: Mechanisms of action and clinical application. JAMA 1991;26:1375-1383.
9. Farrar MA, Schreiber RD. The molecular cell biology of interferon-γ and its receptor. Ann Rev Immunol 1993;11:571-611.
10. Pober JS, Cotran RS. Cytokines and endothelial cell biology. Immunol Rev 1990;70:427-451.
11. David M, Chen, HE, Goelz S, et al. Differential regulation of the alpha/beta interferon-stimulated Jak/Stat pathway by the SH2 domain-containing tyrosine phosphatase SHPTP1. Mol Cell Biol 1995;15:7050-7058.
12. Levy DE, Raz R, Durbin JE, et al. Cytoplasmic transcription factors: Mediators of cytokine signaling. Agents Actions 1995;47(suppl):79-85.
13. Rosenblum MG, Donato NJ. Tumor necrosis factor a: A multi-faceted peptide hormone. Crit Rev Immunol 1989;9:21-44.
14. Pennica D, Nedwin GE, Hayflick JS, et al. Human tumor necrosis factor: Precursor structure, expression, and homology to lymphotoxin. Nature 1984;312:724-729.
15. Gowen M, Wood DD, Ihrie EJ, et al. An interleukin-1 like factor stimulates bone resorption in vitro. Nature 1983;306:378-380.
16. Bertolini DR, Nedwin GE, Bringman TS, et al. Stimulation of bone resorption and inhibition of bone formation in vitro by human tumour necrosis factors. Nature 1986;319:516-518.
17. Bevilacqua MP, Pober JS, Majeau GR, et al. Interleukin-1 (IL-1) induces biosynthesis and cell surface expression of procoagulant activity in human vascular endothelial cells. J Exp Med 1984;160:618-623.
18. Nawroth PP, Stern DM. Modification of endothelial cell hemostatic properties by tumor necrosis factor. J Exp Med 1986;163:740-745.
19. Schmidt JA, Mizel SB, Cohen D, et al. Interleukin-1, a potential regulator of fibroblast proliferation. J Immunol 1982;128: 2177-2182.
20. Vilcek J, Palombella VJ, Henriksen-DeStefano D, et al. Fibroblast growth enhancing activity of tumor necrosis factor and its relationship to other polypeptide growth factors. J Exp Med 1986;163:632-643.
21. Gery I, Gershon RK, Waksman BH. Potentiation of the T lymphocyte response to mitogens: 1. The responding cell. J Exp Med 1972;136:128-142.
22. March CJ, Mosley B, Larsen A, et al. Cloning, sequence, and expression of two distinct human interleukin-1 complementary DNAs. Nature 1985;315:641-645.
23. Dinarello CA. The interleukin-1 family: 10 years of discovery. FASEB J 1994;8:1314-1325.
24. Beg AA, Finco TS, Nantermet PV, et al. Tumor necrosis factor and interleukin-1 lead to phosphorylation and loss of IkBa: A mechanism for NF-kB activation. Mol Cell Biol 1993;13: 3301-3310.
25. Chandra G, Cogswell JP, Miller LR, et al. Cyclic AMP signaling pathways are important in IL-1b transcriptional regulation. J Immunol 1995;155:4535-4543.
26. Loetscher H. Purification and structural properties of two distinct TNF receptors on human cells. In: Aggarwal BB, Vilcek J, eds. Tumor Necrosis Factor: Structure, Function and Mechanism of Action. New York: Marcel Dekker, 1992, pp 161-188.
27. Thoma B, Grell M, Pfizenmaier K, et al. Identification of a 60 kDa tumor necrosis factor (TNF) receptor as the major signal transducing component in TNF responses. J Exp Med 1990;172:1019-1023.
28. Akira S, Taga T, Kishimoto T. Interleukin-6 in biology and medicine. Adv Immunol 1993;54:1-78.
29. Kishimoto T, Akira S, Taga T. Interleukin-6 and its receptor: A paradigm for cytokines. Science 1992;258:593-597.
30. Calandra T, Bernhagen J, Mitchell RA, et al. MIF is a pituitary-derived cytokine that potentiates lethal endotoxaemia. Nature 1993;365:756-759.
31. Nishino T, Bernhagen, J, Shiiki H, et al. Localization of macrophage migration inhibitory factor (MIF) to secretory granules within the corticotrophic and thyrotrophic cells of the pituitary gland. Molec Med 1995;1:781-788.
32. Draft proposals for interleukin nomenclature. Immunol Today 1986;7:321-322.
33. Swain SL. Lymphokines and the immune response: The central role of interleukin-2. Curr Op Immunol 1991;3:304-310.
34. Arai K, Lee F, Miyajima A, et al. Cytokines: Coordinators of immune and inflammatory responses. Ann Rev Biochem 1990;59:783-836.
35. Smith KA. Interleukin-2. Curr Op Immunol 1992;4:271-276.
36. Rubin JT. Interleukin-2: Its biology and clinical application in patients with cancer. Cancer Invest 1993;11:460-472.
37. Janssen RAJ, Mulder NH, The TH, et al. The immunobiological effects of interleukin-2 in vivo. Cancer Immunol Immunother 1994;39:207-216.
38. LeGros G, Ben-Sasson SZ, Seder R, et al. Generation of interleukin 4 (IL-4)-producing cells in vivo and in vitro: IL-2 and IL-4 are required for in vitro generation of IL-4-producing cells. J Exp Med 1990;172:921-929.
39. Swain SL, Weinberg AD, English M, et al. IL-4 directs the development of Th2-like helper effectors. J Immunol 1990;145: 3796-3806.
40. Noelle RJ, Daum J, Bartlett WC, et al. Cognate interactions between helper T cells and B cells. V. Reconstitution of T helper cell function using purified plasma membranes from activated Th1 and Th2 helper T cells and tymphokines. J Immunol 1991;146:1118-1124.
41. Rothman P, Lutzker S, Cook W, et al. Mitogen plus interleukin 4 induction of Ce transcripts in B lymphoid cells. J Exp Med 1988;168:2385-2389.
42. DeVries, JE, Carballido JM, Sornasse T, et al. Antagonizing the differentiation and functions of human T helper type 2 cells. Curr Op Immunol 1995;7:771-778.
43. Zurawski G, de Vries JE. Interleukin 13, an interleukin 4-like cytokine that acts on monocytes and B cells, but not on T cells. Immunol Today 1994;15:19-26.
44. Rousset F, Robert J, Andary M, et al. Shifts in interleukin-4 and interferon-gamma production by T cells of patients with elevated serum IgE levels and the modulatory effects of these lymphokines on spontaneous IgE synthesis. J Allergy Clin Immunol 1991;87:58-69.
45. Hashimoto S, Amemiya E, Tomita Y, et al. Elevation of soluble IL-2 receptor and IL-4, and nonelevation of IFN-gamma in sera from patients with allergic asthma. Ann Allergy 1993;71: 455-458.
46. Jardieu P. Anti-IgE therapy. Curr Op Immunol 1995;7:779-782.
47. Tominaga A, Matsumoto M, Harada, N, et al. Molecular properties and regulation of mRNA expression for murine T cell-replacing factor/IL-5. J Immunol 1988;140:1175-1181.
48. Yamaguchi Y, Matsui T, Kasahara T, et al. In vivo changes of hemopoietic progenitors and the expression of the interleukin 5 gene in eosinophilic mice infected with Toxocara canis. Exp Hematol 1990;18:1152-1157.
49. Plaut M, Pierce JH, Watson CJ, et al. Mast cell lines produce lymphokines in response to cross-linkage of Fc epsilon RI or to calcium ionophores. Nature 1989;339:64-67.
50. Schimpl A, Wecker E. Replacement of T-cell function by a T-cell product. Nature 1972;237:15-17.
51. Takatsu K, Takaki S, Hitoshi Y. Interleukin-5 and its receptor system: Implications in the immune system and inflammation. Adv Immunol 1994;57:145-190.
52. Walsh GM, Hartnell A, Wardlaw AJ, et al. IL-5 enhances the in vitro adhesion of human eosinophils, but not neutrophils, in a leucocyte integrin (CD11/18)-dependent manner. Immunology 1990;71:258-265.
53. Murata Y, Yamaguchi N, Hitoshi Y, et al. Interleukin 5 and interleukin 3 induce serine and tyrosine phosphorylations of several cellular proteins in an interleukin 5-dependent cell line. BBRC 1990;173:1102-1108.
54. Renauld J-C, Kermouni A, Vink, A, et al. Interleukin-9 and its receptor: Involvement in mast cell differentiation and T-cell oncogenesis. J Leuk Biol 1995;57:353-360.
55. Gessner A, Blum H, Röllinghoff M. Differential regulation of IL-9 expression after infection with Leishmania major in susceptible and resistant mice. Immunobiology 1993;189:419-435.
56. Houssiau, FA, Schandené L, Stevens M, et al. A cascade of cytokines is responsible for IL-9 expression in human T cells. J Immunol 1995;154:2624-2630.
57. Houssiau FA, Renauld J-C, Fibbe W, et al. IL-2 dependence of IL-9 expression in human T lymphocytes. J Immunol 1992;148:3147-3151.
58. Uyttenhove C, Simpson RJ, Van Snick J. Functional and structural characterization of P40, a mouse glycoprotein with T-cell growth factor activity. Proc Natl Acad Sci USA 1988;85:6934-6938.
59. Merz H, Houssiau F, Orscheschek K, et al. Interleukin-9 expression in human malignant lymphomas: Unique association with Hodgkin's disease and large cell anaplastic lymphoma. Blood 1991;78:1311-1317.
60. Donahue RE, Yang YC, Clark SC. Human P40 T cell growth factor (interleukin-9) supports erythroid colony formation. Blood 1990;75:2271-2275.
61. Fiorentino DF, Bond MW, Mosmann TR. Two types of mouse T helper cells. IV. TH2 clones secrete a factor that inhibits cytokine production by TH1 clones. J Exp Med 1989;170:2081-2095.
62. Mosmann TR. Properties and functions of interleukin-10. Adv Immunol 1994;56:1-26.
63. Ishida H, Hastings R, Kearney J, et al. Continuous anti-interleukin 10 antibody administration depletes mice of Ly-1 B cells but not conventional B cells. J Exp Med 1992;175:1213-1220.
64. Kuhn R, Rajewsky K, Müller W. IL4 and IL10 deficient mice. 8th International Congress of Immunology 1992;203(Abstr).
65. Wegmann TG, Lin H, Guilbert LJ, et al. Bidirectional cytokine interactions in the maternal-fetal relationship: Is successful pregnancy a TH2 phenomenon? Immunol Today 1993;14: 353-356.
66. Moore KW, O'Garra A, de Waal Malefyt R, et al. Interleukin-10. Ann Rev Immunol 1993;11:165-190.
67. DeVries JE, Zurawaski G. Immunoregulatory properties of IL-13: Its potential role in atopic disease. Int Arch Allergy Immunol 1995;106:175-179.
68. Punnonen J, Cocks BG, de Vries JE. IL-4 induces germ-line IgE heavy chain gene transcription in human fetal pre-B cells: Evidence for differential expression of functional IL-4 and IL-13 receptors during B cell ontogeny. J Immunol 1995;155:4248-4254.
69. Pawankar RU, Okuda M, Hasegawa S, et al. Interleukin-13 expression in the nasal mucosa of perennial allergic rhinitis. Am J Resp Crit Care Med 1995;152:2059-2067.
70. Kim C, Schinkel C, Fuchs D, et al. Interleukin-13 effectively down-regulates the monocyte inflammatory potential during traumatic stress. Arch Surgery 1995;130:1330-1336.
71. Ambrus JL Jr, Chesky L, Chused T, et al. Intracellular signaling events associated with induction of proliferation of normal human B lymphocytes by two different antigenically related human B cell growth factors (high molecular weight B cell growth factor [HMW-BCGF] and the complement factor 3b). J Biol Chem 1991;266:3702-3708.
72. Ambrus JL Jr, Pippin J, Joseph A, et al. Identification of a cDNA for human high-molecular-weight B-cell growth factor. Proc Natl Acad Sci USA 1993;90:6330-6334.
73. Ford R, Tamayo A, Martin B, et al. Identification of B-cell growth factors (interleukin-14; high molecular weight-B-cell growth factors) in effusion fluids from patients with aggressive B-cell lymphomas. Blood 1995;86:283-293.
74. Yao Z, Painter SL, Fanslow WC, et al. Human IL-17: A novel cytokine derived from T cells. J Immunol 1995;155:5483-5486.
75. D'Andrea A, Rengaraju M, Valiante NM, et al. Production of natural killer cell stimulatory factor (NKSF/IL-12) by peripheral blood mononuclear cells. J Exp Med 1992;176:1387-1398.
76. Trinchieri G. Interleukin-12: A proinflammatory cytokine with immunoregulatory functions that bridge innate resistance and antigen-specific adaptive immunity. Ann Rev Immunol 1995;13:251-276.
77. Maruo S, Toyo-oka K, Oh-hora M, et al. IL-12 produced by antigen-presenting cells induces IL-2-independent proliferation of T helper cell clones. J Immunol 1996;156:1748-1755.
78. Kobayashi M, Fitz L, Ryan M, et al. Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biologic effects on human lymphocytes. J Exp Med 1989;170:827-846.
79. Gazzinelli RT, Hieny S, Wynn TA, et al. Interleukin-12 is required for the T-lymphocyte independent induction of interferon-γ by an intracellular parasite and induces resistance in T-deficient hosts. Proc Natl Acad Sci USA 1993;90:6115-6119.
80. Tripp CS, Gately MK, Hakimi J, et al Neutralization of IL-12 decreases resistance to Listeria in SCID and CB-17 mice. J Immunol 1994;152:1883-1887
81. Wynn TA, Eltoum I, Oswald IP, et al. Endogenous interleukin 12 (IL-12) regulates granuloma formation induced by eggs of Schistomsoma mansoni and endogenous IL-12 both inhibits and prophylactically immunizes against egg pathology. J Exp Med 1994;179:1551-1561.
82. Grabstein KH, Eisenman J, Shanebeck K, et al. Cloning of a T-cell growth factor that interacts with the beta chain of the interleukin-2 receptor. Science 1994;264:965-968.
83. Giri JG, Anderson DM, Kumaki S, et al. IL-15, a novel T cell growth factor that shares activities and receptor components with IL-2. J Leuk Biol 1995;57:763-766.
84. Gamero AM, Ussery D, Reintgen DS, et al. Interleukin 15 induction of lymphokine-activated killer cell function against autologous tumor cells in melanoma patient lymphocytes by a CD18-dependent, perforin-related mechanism. Cancer Res 1995;55:4988-4994.
85. Munger W, DeJoy SQ, Jeyaseelan R Sr, et al. Studies evaluating the antitumor activity and toxicity of interleukin-15, a new T cell growth factor: comparison with interleukin-2. Cell Immunol 1995;165:289-293.
86. Baggliolini M, DeWald B, Moser B. Interleukin-8 and related chemotactic cytokines: CXC and CC chemokines. Adv Immunol 1994;55:97-179.
87. Raport CJ, Schweickart VL, Chantry D, et al. New members of the chemokine receptor gene family. J Leuk Biol 1996;59:18-23.
88. Strieter RM, Kunkel SL, Showell HJ, et al. Endothelial cell gene expression of a neutrophil chemotactic factor by TNF, IL-1, and LPS. Science 1989;243:1467-1469.
89. Dixit VM, Green S, Sarma V, et al. Tumor necrosis factor: A induction of novel gene products in human endothelial cells including a macrophage-specific chemotaxin. J Biol Chem 1990;265:2973-2978.
90. Thelen M, Peveri P, Kernen P, et al. Mechanism of neutrophil activation by NAF: A novel monocyte-derived peptide agonist. FASEB J 1988;2:2702-2706.
91. Westlin WF, Kiely J-M, Gimbrone MA Jr. Interleukin-8 induces changes in human neutrophil actin conformation and distribution: Relationship to inhibition of adhesion to cytokine-activated endothelium. J Leuk Biol 1992;52:43-51.
92. Masure S, Proost P, Van Damme J, et al. Purification and identification of 91-kDa neutrophil gelatinase: Release by the activating peptide interleukin-8. Eur J Biochem 1991;198:391-398.
93. Schröder JM. The monocyte-derived neutrophil activated peptide (NAP/interleukin 8) stimulates human neutrophil arachidonate-5-lipoxygenase, but not the release of cellular arachidonate. J Exp Med 1989;170:847-863.
94. Yoshimura T, Robinson EA, Tanaka S, et al. Purification and amino acid analysis of two human monocyte chemoattractants produced by phytohemagglutinin-stimulated human blood mononuclear leukocytes. J Immunol 1989;142:1956-1962.
95. Yoshimura T, Robinson EA, Tanaka S, et al. Purification and amino acid analysis of two human glioma-derived monocyte chemoattractants. J Exp Med 1989;169:1449-1459.
96. Matsushima K, Larsen CG, DuBois GC, et al. Purification and characterization of a novel monocyte chemotactic and activating factor produced by a human myelomonocytic cell line. J Exp Med 1989;169:1485-1490.
97. Proost P, Wuyts A, Van Damme J. Human monocyte chemotactic proteins-2 and -3: structural and functional comparison with MCP-1. J Leuk Biol 1996;59:67-74.
98. Cook DN. The role of MIP-1α in inflammation and hematopoiesis. J Leuk Biol 1996;59:61-66.
99. Cruikshank WW, Center DM, Nisar N, et al. Molecular and functional analysis of a lymphocyte chemoattractant factor: Association of biologic function with CD4 expression. Proc Natl Acad Sci USA 1994;91:5109-5113.
100. Keiner GS, Kennedy J, Bacon KB, et al. Lymphotactin: A cytokine that represents a new class of chemokine. Science 1994;266:1395-1399.
101. + T cells is independent of transcription and translation: Evidence for constitutive protein synthesis and storage. J Immunol 1995;155:2902-2910.
102. + T cells in vitro. J Immunol 1996;156:310-315.
103. Cruikshank WW, Long A, Tarpy RE, et al. Early identification of interleukin-16 (lymphocyte chemoattractant factor) and macrophage inflammatory protein 1 alpha (MIP-1α) in bronchoalveolar lavage fluid of antigen-challenged asthmatics. Am J Resp Cell Mol Biol 1995;13:738-747.
104. Lloyd AR, Oppenheim JJ, Kelvin DJ, et al. Chemokines regulate T cell adherence to recombinant adhesion molecules and extracellular matrix proteins. J Immunol 1996;156:932-938.
105. Rot A, Hub E, Middleton J, et al. Some aspects of IL-8 pathophysiology III: Chemokine interaction with endothelial cells. J Leuk Biol 1996;59:39-44.
106. Bradley TR, Metcalf D. The growth of mouse bone marrow cells in vitro. Aust J Exp Biol Med Sci 1966;44:287-300.
107. Vose JM, Armitage JO. Clinical applications of hematopoietic growth factors. J Clin Oncol 1995;13:1023-1035.
108. Komschlies KL, Grzegorzewski K, Wiltrout RH. Diverse immunological and hematological effects of interelukin 7: Implications for clinical application. J Leuk Biol 1995;58:623-633.
109. Goldman SJ. Preclinical biology of interleukin 11: A multifunctional hematopoietic cytokine with potent thrombopoietic activity. Stem Cells 1995;13:462-471.
110. Williams DE. Optimizing the effectiveness of hematopoietic growth factors. J Clin Immunol 1994;14:215-223.
111. Attisano L, Wrana JL, López-Casillas F, et al. TGF-β receptors and actions. Biochima et Biophysica Acta 1994;1222:71-80.
112. Derynck R. TGF-β receptor-mediated signaling. TIBS 1994;19: 548-553.
113. Beck LS, DeGuzman L, Lee WP, et al. One systemic administration of transforming growth factor-β1 reverses age- or glucocorticoid-impaired wound healing. J Clin Invest 1993;92: 2841-2849.
114. Derynck R, Lindquist PB, Lee A, et al. A new type of transforming growth factor-β, TGF-β3. EMBO J 1988;7:3737-3743.
115. Wahl S.M. Transforming growth factor beta (TGF-β) in inflammation: A cause and a cure. J Clin Immunol 1992;12:61-74.
116. Shull MM, Ormsby I, Kier AB, et al. Targeted disruption of the mouse transforming growth factor-β1 gene results in multifocal inflammatory disease. Nature 1992;359:693-699.
117. Kulkarni AB, Huh C-G, Becker D, et al. Transforming growth factor β1 null mutation in mice causes excessive inflammatory response and early death. Proc Natl Acad Sci USA 1993;90: 770-774.
118. Roberts AB, Sporn MB. Physiological actions and clinical applications of transforming growth factor-β (TGF-β). Growth Factors 1993;8:1-9.
119. Border WA, Ruoslahti E. Transforming growth factor-β in disease: The dark side of tissue repair. J Clin Invest 1992;90:1-7.
120. Murthy US, Anzano MA, Stadel JM, et al Coupling of TGF-β-induced mitogenesis to G-protein activation in AKR-2B cells. BBRC 1988;152:1228-1235.
121. Kataoka R, Sherlock J, Lanier SM. Signaling events initiated by transforming growth factor-beta 1 that require Gi alpha 1. J Biol Chem 1993;268:19851-19857.
122. Bereta J, Bereta M, Coffman FD, et al. Inhibition of basal and tumor necrosis factor-enhanced binding of murine tumor cells to murine endothelium by transforming growth factor-β. J Immunol 1992;148:2932-2940.
123. Ohtsuki M, Massagué J. Evidence for the involvement of protein kinase activity in transforming growth factor-β signal transduction. Mol Cell Biol 1992;12:261-265.
124. Gruppuso PA, Mikumo R, Brautigan DL, et al. Growth arrest induced by transforming growth factor beta 1 is accompanied by protein phosphatase activation in human keratinocytes. J Biol Chem 1991;266:3444-3448.
125. Liles WC, Van Voorhis WC. Review: Nomenclature and biologic significance of cytokines involved in inflammation and the host immune response. J Infect Dis 1995;172:1573-1580.